Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.92
NVGN's Cash to Debt is ranked lower than
62% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.35 vs. NVGN: 0.92 )
Ranked among companies with meaningful Cash to Debt only.
NVGN' s 10-Year Cash to Debt Range
Min: 0.92  Med: 68.59 Max: No Debt
Current: 0.92
Equity to Asset 0.32
NVGN's Equity to Asset is ranked lower than
86% of the 575 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. NVGN: 0.32 )
Ranked among companies with meaningful Equity to Asset only.
NVGN' s 10-Year Equity to Asset Range
Min: 0.32  Med: 0.75 Max: 0.86
Current: 0.32
0.32
0.86
F-Score: 2
Z-Score: -40.60
M-Score: -7.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -13118.75
NVGN's Operating margin (%) is ranked lower than
99% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.92 vs. NVGN: -13118.75 )
Ranked among companies with meaningful Operating margin (%) only.
NVGN' s 10-Year Operating margin (%) Range
Min: -7650.57  Med: -130.62 Max: -31.89
Current: -13118.75
-7650.57
-31.89
Net-margin (%) -10406.25
NVGN's Net-margin (%) is ranked lower than
99% of the 671 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.96 vs. NVGN: -10406.25 )
Ranked among companies with meaningful Net-margin (%) only.
NVGN' s 10-Year Net-margin (%) Range
Min: -8583.91  Med: -90.55 Max: 90.46
Current: -10406.25
-8583.91
90.46
ROE (%) -139.60
NVGN's ROE (%) is ranked lower than
97% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.43 vs. NVGN: -139.60 )
Ranked among companies with meaningful ROE (%) only.
NVGN' s 10-Year ROE (%) Range
Min: -269.02  Med: -32.79 Max: 33.98
Current: -139.6
-269.02
33.98
ROA (%) -85.26
NVGN's ROA (%) is ranked lower than
96% of the 718 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.50 vs. NVGN: -85.26 )
Ranked among companies with meaningful ROA (%) only.
NVGN' s 10-Year ROA (%) Range
Min: -143.49  Med: -27.43 Max: 12.06
Current: -85.26
-143.49
12.06
ROC (Joel Greenblatt) (%) -37776.00
NVGN's ROC (Joel Greenblatt) (%) is ranked lower than
98% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.24 vs. NVGN: -37776.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -9586.01  Med: -348.56 Max: -53.89
Current: -37776
-9586.01
-53.89
Revenue Growth (3Y)(%) -100.00
NVGN's Revenue Growth (3Y)(%) is ranked lower than
99% of the 548 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. NVGN: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVGN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100  Med: -19.10 Max: 2
Current: -100
-100
2
EBITDA Growth (3Y)(%) -28.60
NVGN's EBITDA Growth (3Y)(%) is ranked lower than
87% of the 494 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. NVGN: -28.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVGN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -65.3  Med: -17.50 Max: 31.5
Current: -28.6
-65.3
31.5
EPS Growth (3Y)(%) -14.50
NVGN's EPS Growth (3Y)(%) is ranked lower than
72% of the 455 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. NVGN: -14.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVGN' s 10-Year EPS Growth (3Y)(%) Range
Min: -62.5  Med: -14.50 Max: 24.1
Current: -14.5
-62.5
24.1
» NVGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

NVGN Guru Trades in Q2 2013

Jim Simons 15,240 sh (-66.09%)
» More
Q3 2013

NVGN Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q1 2015

NVGN Guru Trades in Q1 2015

Jim Simons 103,200 sh (New)
» More
Q2 2015

NVGN Guru Trades in Q2 2015

Jim Simons 215,600 sh (+108.91%)
» More
» Details

Insider Trades

Latest Guru Trades with NVGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.27
NVGN's P/B is ranked lower than
69% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.05 vs. NVGN: 4.27 )
Ranked among companies with meaningful P/B only.
NVGN' s 10-Year P/B Range
Min: 0.95  Med: 3.98 Max: 13.53
Current: 4.27
0.95
13.53
P/S 368.99
NVGN's P/S is ranked lower than
134% of the 664 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.08 vs. NVGN: 368.99 )
Ranked among companies with meaningful P/S only.
NVGN' s 10-Year P/S Range
Min: 0  Med: 10.40 Max: 369.15
Current: 368.99
0
369.15
Current Ratio 0.81
NVGN's Current Ratio is ranked lower than
94% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. NVGN: 0.81 )
Ranked among companies with meaningful Current Ratio only.
NVGN' s 10-Year Current Ratio Range
Min: 0.81  Med: 6.08 Max: 9.78
Current: 0.81
0.81
9.78
Quick Ratio 0.81
NVGN's Quick Ratio is ranked lower than
84% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. NVGN: 0.81 )
Ranked among companies with meaningful Quick Ratio only.
NVGN' s 10-Year Quick Ratio Range
Min: 0.81  Med: 5.22 Max: 8.68
Current: 0.81
0.81
8.68
Days Sales Outstanding 501.88
NVGN's Days Sales Outstanding is ranked lower than
99% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.80 vs. NVGN: 501.88 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVGN' s 10-Year Days Sales Outstanding Range
Min: 1.51  Med: 73.36 Max: 404.33
Current: 501.88
1.51
404.33

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 3.09
NVGN's Price/Tangible Book is ranked lower than
59% of the 590 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. NVGN: 3.09 )
Ranked among companies with meaningful Price/Tangible Book only.
NVGN' s 10-Year Price/Tangible Book Range
Min: 1.49  Med: 4.83 Max: 19.3
Current: 3.09
1.49
19.3
Price/Median PS Value 59.50
NVGN's Price/Median PS Value is ranked lower than
149% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.26 vs. NVGN: 59.50 )
Ranked among companies with meaningful Price/Median PS Value only.
NVGN' s 10-Year Price/Median PS Value Range
Min: 0.45  Med: 0.93 Max: 3.16
Current: 59.5
0.45
3.16
Earnings Yield (Greenblatt) (%) -22.07
NVGN's Earnings Yield (Greenblatt) (%) is ranked lower than
92% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. NVGN: -22.07 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVGN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -22.07  Med: 1594.10 Max: 3288.7
Current: -22.07
-22.07
3288.7

Analyst Estimate

Jun15 Jun16 Jun17 Jun18
Revenue(Mil) 1 1 3 2
EPS($) -0.01 -0.02 -0.01 -0.02
EPS without NRI($) -0.01 -0.02 -0.01 -0.02

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:NRT.Australia, NV9B.Germany, NV9.Germany, NVGNF.USA,
Novogen Ltd. was incorporated in March 1994 under the jurisdiction of the laws of New South Wales, Australia. The Company is engaged in pharmaceutical drug development. It develops single drug capable of killing both the dominant differentiated cells in a cancer as well as the undifferentiated cancer stem cells at a therapeutic dose. The Company's inaugural drug candidate CS-6 belongs to a new class of drug candidates known as Mitochondrial Electron Transfer Inhibitors that work by depriving the cancer cell of its main energy source. The Company's competitors include pharmaceutical companies and biotechnology companies, as well as universities and public and private research institutions. The activities of the Company are subject to numerous Australian laws and regulations.
» More Articles for NVGN

Headlines

Articles On GuruFocus.com
Novogen (NVGN) Promising Data in Brain Cancer; eFuture Information Technology (EFUT) and NeoPhotonic Mar 04 2015 
comment on NVGN Mar 06 2013 

More From Other Websites
Novogen (NVGN) Conducts Scientific Review of R&D Program Aug 31 2015
Novogen Announces The Outcome Of A Comprehensive Science Review Aug 30 2015
Newly Appointed Acting CEO Outlines Immediate Plans for Novogen Jul 29 2015
Novogen Appoints Iain Ross as Acting CEO and Re-appoints Him to the Board Jul 21 2015
Anisina Receives Orphan Drug Designation from FDA for Neuroblastoma Jul 16 2015
Pre-clinical Studies Suggest Anisina May Improve Chemotherapy Effectiveness in Childhood Cancer Jul 13 2015
H.C. Wainwright: Time To Buy Novogen Jul 01 2015
Coverage initiated on Novogen by H.C. Wainwright Jul 01 2015
Novogen Announces the Chairman's Address at the Company's General Meeting Jun 23 2015
Anisina on Track to Enter Clinic in 2016 Jun 23 2015
StockNewsNow.com Publishes New SNNLive Video Interview With Novogen Limited Jun 16 2015
Novogen to Present at Bio International Convention Philadelphia 2015 Jun 11 2015
Studies Confirm TRXE-009 Crosses the Blood-brain Barrier Jun 04 2015
Novogen Expands Board with Two New Appointments Jun 02 2015
Novogen Limited Announces Closing of Rights Issue Entitlement Offer and Notice of Shortfall Jun 01 2015
ATM Technology Extended with New Patent Lodgement May 27 2015
Novogen to Present at Brain Tumor Biotech Summit 2015 May 26 2015
Novogen to Present at the 2015 Marcum Microcap Conference May 25 2015
Novogen to Present at Hong Kong Investor Conference May 17 2015
Anisina Confirmed as Effective Anti-Cancer Agent in Animal Studies May 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK